February 8, 2019 Liq. Handling & Robotics M&A, Partnerships Product Launch

Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research

Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories. Andrew Alliance S.A. and Sartorius today announced the launch of the Andrew Alliance Pipette+ system, which uniquely provides both full traceability and improved repeatability in manual pipetting for life science laboratories. Andrew Alliance, the robotics company... Read more

February 7, 2019 Environ, Ag./Food & Bev M&A, Partnerships

bioMérieux acquires Invisible Sentinel, a US-based company specialized in food and beverage molecular testing

Marcy l’Étoile, France 07 February, 2019 bioMérieux, a global player in in vitro diagnostics and world leader in food microbiology testing, today announced the acquisition of Invisible Sentinel Inc. This company, based in Philadelphia (PA) develops, manufactures and markets innovative and user-friendly molecular diagnostic tools for the rapid, accurate and reliable detection of pathogens and spoilage organisms in... Read more

February 7, 2019 Chromatography Lab Top-10 M&A, Partnerships Mass Spectrometry

Andrew Alliance and Waters Corporation Partner to Provide Tailored Tools for LC-MS Research

GENEVA, February 6, 2019 /PRNewswire/ — New Liquid Chromatography and Mass Spectrometry Tools Through New Partnership  Andrew Alliance S.A., the robotics company that is improving repeatability with an innovative approach to liquid handling using conventional laboratory pipettes, and Waters Corporation (NYSE: WAT), today announced a new strategic partnership agreement to improve laboratory operations in the... Read more

February 7, 2019 Cell Analysis Tools M&A, Partnerships

Lonza and AllCells Join Forces for Global Commercialization of Hematopoietic Primary Cells

Walkersville, MD (USA) / Basel (CH), 7 February 2019 – Lonza and AllCells have entered into a private label partnership for the manufacture and global commercialization of an extensive range of hematopoietic primary cells. This partnership expands Lonza’s broad offering of hematopoietic cell lines and enables cell biologists to easily access a wide selection of... Read more

February 7, 2019 Cell Analysis Tools Clinical Research/Diagn. M&A, Partnerships Mass Spectrometry

Fluidigm Announces Participation in Life Science/Pharma and Academic Consortium to Study T Cell-Driven Immune-Mediated Inflammatory Diseases

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ: FLDM) today announced it is one of 11 partners in the TIMID Consortium, a unique effort of six academic institutions and five life science and pharma companies that utilizes both mass cytometry and Imaging Mass Cytometry™ along with other technologies to explore the common cellular basis of... Read more

February 7, 2019 Clinical Research/Diagn. M&A, Partnerships

Fluidigm Announces Co-Marketing Agreement with Indica Labs to Offer Platform for Imaging Mass Cytometry Data Analysis to Aid Novel Digital Pathology Investigations

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ: FLDM) and Indica Labs, Inc., today announced a co-marketing relationship for scalable and simple-to-use tissue image analysis for Imaging Mass Cytometry™ (IMC™). Under the terms of the agreement, Fluidigm and Indica Labs will cooperatively promote the next-generation digital pathology image analysis and image management platforms HALO®, HALO AI™and HALO Link™ in conjunction with... Read more

February 6, 2019 M&A, Partnerships

Pathios Therapeutics and Sygnature Discovery sign a strategic and innovative partnership to develop first in class therapies in autoimmune disease and immuno-oncology

OXFORD and Nottingham UK, 06 FEBRUARY 2019: Pathios Therapeutics (“Pathios”), an innovative biotech company focused on the development of first in class therapies for autoimmune diseases and immuno-oncology and Sygnature Discovery (“Sygnature”), jointly announce a strategic partnership to accelerate Pathios’ drug discovery and development programmes. As part of the agreement, Pathios and Sygnature will collaborate... Read more

February 5, 2019 M&A, Partnerships

Teledyne Completes Acquisition of Scientific Imaging Businesses of Roper Technologies

THOUSAND OAKS, Calif. and SARASOTA, Fla. – February 5, 2019 – Teledyne Technologies Incorporated (NYSE:TDY) (“Teledyne”) and Roper Technologies, Inc. (NYSE:ROP) (“Roper”) jointly announced today the successful completion of the previously announced acquisition by Teledyne of the Scientific Imaging businesses of Roper for $225 million in cash. The Scientific Imaging businesses include Princeton Instruments, Photometrics... Read more

February 5, 2019 Clinical Research/Diagn. M&A, Partnerships

FALCO biosystems and Promega Corporation MSI-IVD Kit Collaboration Obtains Approved Companion Diagnostic Status in Japan

Madison, WI USA. (February 5, 2019) Promega Corporation today announced FALCO biosystems of Kyoto, Japan, a core business company of FALCO HOLDINGS, working in collaboration with Promega microsatellite instability (MSI) chemistry and assay design, obtained companion diagnostic approval for FALCO’s MSI-IVD from Japan’s regulatory agency, the Ministry of Health, Labour and Welfare (MHLW). The MSI-IVD Kit (FALCO),... Read more

February 4, 2019 Clinical Research/Diagn. M&A, Partnerships

Bio-Techne Signs Strategic Cooperation Agreement With Lisen Imprinting Diagnostics

FEBRUARY 26, 2019 MINNEAPOLIS, Feb. 26, 2019 /PRNewswire/ — Bio-Techne has entered into a strategic cooperation agreement in the precision medicine field with Lisen Imprinting Diagnostics Wuxi Co., Ltd, China. Liwen Pei, Managing Director of Bio-Techne China, and Ning Zhou, CEO of Lisen, attended the meeting and signing ceremony. Bio-Techne is a leading provider of high-quality... Read more